Tegaserod -: A serotonin 5-HT4 receptor agonist for treatment of constipation-predominant irritable bowel syndrome

被引:7
作者
Cole, P [1 ]
Rabasseda, X [1 ]
机构
[1] Prous Sci, Dept Med Informat, Barcelona 08025, Spain
关键词
D O I
10.1358/dot.2004.40.12.872576
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Activation of serotonin 5-HT4 receptors has been proposed as treatment for irritable bowel syndrome, a common, complex and distressing gastrointestinal disorder. Abnormal intestinal motility and sensitivity in irritable bowel syndrome patients can result in diarrhea, constipation, abdominal pain, bloating, headache and fatigue; these and other symptoms can lead to exacerbation of psychological stress, which may in turn induce further physiological abnormalities and patient discomfort. The serotonin agonist tegaserod binds with high affinity to 5-HT4 receptors and has demonstrated potent pharmacological effects on the mid- and distal gut. Tegaserod has been safely employed in clinical trials where it has demonstrated efficacy in normalizing intestinal function, thereby improving irritable bowel syndrome Symptoms. (C) 2004 Prous Science. All rights reserved.
引用
收藏
页码:1013 / 1030
页数:18
相关论文
共 83 条
[1]   First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine(4) receptor agonist [J].
Appel, S ;
Kumle, A ;
Hubert, M ;
Duvauchelle, T .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (03) :229-237
[2]   Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit [J].
Appel, S ;
Kumle, A ;
Meier, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (05) :546-555
[3]   The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects - male and female, elderly and young [J].
Appel-Dingemanse, A ;
Horowitz, A ;
Campestrini, J ;
Osborne, S ;
McLeod, J .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (07) :937-944
[4]   Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration [J].
Appel-Dingemanse, S ;
Lemarechal, MO ;
Kumle, A ;
Hubert, M ;
Legangneux, E .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (05) :483-491
[5]   Clinical pharmacokinetics of tegaserod, a serotonin 5-HT4 receptor partial agonist with promotile activity [J].
Appel-Dingemanse, S .
CLINICAL PHARMACOKINETICS, 2002, 41 (13) :1021-1042
[6]   Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919) [J].
Appel-Dingemanse, S ;
Hirschberg, Y ;
Osborne, S ;
Pommier, F ;
McLeod, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 56 (12) :889-891
[7]  
APPELDINGE C, 1999, GUT S5, V45
[8]   New horizons in the treatment of irritable bowel syndrome [J].
Bamba, T ;
Fuse, K .
DRUGS OF TODAY, 1999, 35 (01) :5-12
[9]   The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study [J].
Bardhan, KD ;
Forbes, A ;
Marsden, CL ;
Mason, T ;
Short, G .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (02) :213-222
[10]   THE SEROTONIN 5-HT4 RECEPTOR .2. STRUCTURE-ACTIVITY STUDIES OF THE INDOLE CARBAZIMIDAMIDE CLASS OF AGONISTS [J].
BUCHHEIT, KH ;
GAMSE, R ;
GIGER, R ;
HOYER, D ;
KLEIN, F ;
KLOPPNER, E ;
PFANNKUCHE, HJ ;
MATTES, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (13) :2331-2338